Onconetix (ONCO) Osake Kurssi

Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. The company is headquartered in Cincinnati, Ohio and currently employs 12 full-time employees. The company went IPO on 2022-02-18. The firm is focused on developing transformational therapies to address significant health challenges globally. The firm is engaged in developing a streptococcus pneumonia vaccine candidate, designed to specifically prevent highly infectious middle ear infections, known as acute otitis media (AOM), in children, and prevention of pneumonia in the elderly. The firm is also developing a universal flu vaccine that provides protection from all virulent strains in addition to licensing a norovirus (NoV) shell and protrusion (S&P) nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children’s Hospital Medical Center to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, among others. In addition, the Company is developing a Chlamydia vaccine candidate with the University of Texas Health Science Center in San Antonio (UT Health).